ProKidney Corp. ( PROK ) stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.

What happened: The chronic kidney disease (CKD)-focused company reported statistically significant and clinically meaningful positive topline results from the full Group 1 modified intent-to-treat (mITT) population of the Phase 2 REGEN-007 trial of rilparencel in patients with CKD and diabetes.

Rilparencel is an autologous cellular therapy. It is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.

Also Read: FDA Raises Manufacturing Concerns, Delays Unicycive’s Kidney Disease Drug Approval

In Group 1 (n=24), kidney function stabilized after receiving rilparencel. The annual decline in estimated glomerular filtration rate (eGFR) slope improved by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 in the period following the last rilparencel injection.

This 4.6 mL/min/1.73m2 per year difference was statistically significant (p